Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

Y-C Shen; C Hsu; J-Y Chen; A-L Cheng

doi:10.1038/sj.bjc.6602200

Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

Br J Cancer. 2004 Oct 18;91(8):1561-5. doi: 10.1038/sj.bjc.6602200.

Authors

Y-C Shen¹, C Hsu, J-Y Chen, A-L Cheng

Affiliation

¹ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

Abstract

Although the PPARgamma agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1-10 microM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid. Furthermore, no synergistic effect was found between troglitazone and cytotoxic anticancer agents.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Apoptosis / drug effects*
Carcinoma, Hepatocellular / metabolism
Carcinoma, Hepatocellular / pathology*
Cell Division / drug effects
Chromans / administration & dosage
Dose-Response Relationship, Drug
Drug Synergism
Humans
Liver Neoplasms / metabolism
Liver Neoplasms / pathology*
Thiazolidinediones / administration & dosage
Tretinoin / administration & dosage
Troglitazone
Tumor Cells, Cultured

Substances

Chromans
Thiazolidinediones
Tretinoin
Troglitazone